Cat. No. | Product name | CAS No. |
DC7141 |
Omipalisib
Featured
GSK2126458 is a highly selective and potent inhibitor of PI3K with Ki of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2 , respectively. |
1086062-66-9 |
DC9943 |
PI3Kδ inhibitor GS2269557
GSK-2269557 is a potent and selective PI3Kδ inhibitor over the closely related isoforms. |
1254036-71-9 |
DC9944 |
PI3Kδ inhibitor GS2292767
GSK2292767 is a potent and selective PI3Kδ inhibitor. |
1254036-66-2 |
DC2070 |
GSK690693
Featured
GSK690693 is a pan-Akt inhibitor targeting Akt1, Akt2 and Akt3 with IC50 of 2 nM, 13 nM, and 9 nM, respectively. |
937174-76-0 |
DC10061 |
PI4KA inhibitor-A1
Featured
GSK-A1 is a potent inhibitor of PI4KA. In vitro using HEK-AT1 cells, GSK-A1 had an IC50 of about 3 nM. |
1416334-69-4 |
DC7705 |
HTH-01-015
Featured
HTH-01-015 is a selective inhibitor of NUAK1 kinase with an IC50 value of 100 nM. |
1613724-42-7 |
DC7156 |
IC-87114
Featured
IC-87114 was the first isoform-selective PI3K inhibitor. p110δ(IC50 = 0.13 μM) vs. p110α(IC50 = 200 μM), p110β(IC50 = 16 μM) and p110γ(IC50 = 61 μM). |
371242-69-2 |
DC11151 |
ICSN3250 hydrochloride
ICSN3250 (ICSN-3250) hydrochloride is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors. |
1561902-79-1 |
DC11150 |
ICSN3250
ICSN3250 (ICSN-3250) is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors. |
1561902-73-5 |
DC7171 |
INK-128(Sapanisertib)
Featured
INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms. |
1224844-38-5 |
DC7873 |
INK-055 (PI3Kγ inhibitor 1)
INK055 is a dual PI3Kg/d inhibitor. |
1172118-03-4 |
DC5072 |
Duvelisib (IPI-145, INK1197)
Featured
IPI-145 is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. |
1201438-56-3 |
DC9829 |
IPI-549
Featured
IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. |
1693758-51-8 |
DC10746 |
KDU691
Featured
KDU691 is a PI4K inhibitor. |
1513879-19-0 |
DC3101 |
Ku-0063794
KU-0063794 is a potent and highly specific mTOR inhibitor for both mTORC1 and mTORC2 with IC50 ~10 nM. |
938440-64-3 |
DC12386 |
Leniolisib (CDZ173)
Featured
Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor currently in phase II/III clinical trials for the treatment of immunodeficiency disorders. |
1354690-24-6 |
DC10754 |
LX2343
Featured
LX-2343 is a novel non-ATP competitive PI3K inhibitor, negatively regulating AKT/mTOR signaling, thus promoting autophagy, and increasing A-beta clearance. |
333745-53-2 |
DC1058 |
LY294002
Featured
LY294002 is a PI3K inhibitor for p110α, p110δ and p110β with IC50 of 0.5 μM, 0.57 μM and 0.97 μM, respectively. |
154447-36-6 |
DC10219 |
LY3023414
Featured
LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK. |
1386874-06-1 |
DC7210 |
LY-303511(Nv-128)
Featured
LY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K. |
154447-38-8 |
DC10015 |
MELK-8a
Featured
MELK-8a is a novel MELK inhibitor. |
1922153-17-0 |
DC11465 |
MELK-T1
Featured
MELK-T1 is a potent and selective inhibitor of protein kinase MELK. |
1610586-62-3 |